Phase-2 study of Tarceva [erlotinib] in patients with recurrent phospho-Akt negative glioblastoma multiforme and gliosarcoma.

Trial Profile

Phase-2 study of Tarceva [erlotinib] in patients with recurrent phospho-Akt negative glioblastoma multiforme and gliosarcoma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 25 Nov 2014

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Glioblastoma; Gliosarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Jan 2013 Additional lead trial centre added as reported by ClinicalTrials.gov record.
    • 15 Dec 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 28 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top